123 related articles for article (PubMed ID: 36856175)
1. Anlotinib Inhibits Proliferation and Induces Apoptosis in B-cell Acute Lymphoblastic Leukemia by Targeting the BTK and AKT/mTOR Pathway.
Shi X; Li S; Tang S; Lu Y
Anticancer Agents Med Chem; 2023; 23(12):1397-1405. PubMed ID: 36856175
[TBL] [Abstract][Full Text] [Related]
2. Anlotinib inhibits the proliferation and induces apoptosis by inactivating the AKT pathway in androgen receptor-negative prostate cancer cells.
Xu Y; Zheng J; Ye ZY
Neoplasma; 2022 Sep; 69(5):1119-1128. PubMed ID: 36004650
[TBL] [Abstract][Full Text] [Related]
3. Marsdenia tenacissimae extraction (MTE) inhibits the proliferation and induces the apoptosis of human acute T cell leukemia cells through inactivating PI3K/AKT/mTOR signaling pathway via PTEN enhancement.
Wang Y; Chen B; Wang Z; Zhang W; Hao K; Chen Y; Li K; Wang T; Xie Y; Huang Z; Tong X
Oncotarget; 2016 Dec; 7(50):82851-82863. PubMed ID: 27756877
[TBL] [Abstract][Full Text] [Related]
4. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
Guo Y; Shan Q; Gong Y; Lin J; Yang X; Zhou R
Cancer Biol Ther; 2012 Nov; 13(13):1244-54. PubMed ID: 22895079
[TBL] [Abstract][Full Text] [Related]
5. [Paeoniflorin induces apoptosis and cycle arrest in B-cell acute lymphoblastic leukemia cells by inhibiting SENP1/c-Myc signaling pathway].
Qin X; Chen X; Liu J; Zeng Y; Guo L; Liu WJ
Zhongguo Zhong Yao Za Zhi; 2022 Jun; 47(12):3312-3319. PubMed ID: 35851125
[TBL] [Abstract][Full Text] [Related]
6. Resveratrol induces apoptosis and autophagy in T-cell acute lymphoblastic leukemia cells by inhibiting Akt/mTOR and activating p38-MAPK.
Ge J; Liu Y; Li Q; Guo X; Gu L; Ma ZG; Zhu YP
Biomed Environ Sci; 2013 Nov; 26(11):902-11. PubMed ID: 24331535
[TBL] [Abstract][Full Text] [Related]
7. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
[TBL] [Abstract][Full Text] [Related]
8. Resistance to TRAIL-induced apoptosis caused by constitutional phosphorylation of Akt and PTEN in acute lymphoblastic leukemia cells.
Dida F; Li Y; Iwao A; Deguchi T; Azuma E; Komada Y
Exp Hematol; 2008 Oct; 36(10):1343-53. PubMed ID: 18599181
[TBL] [Abstract][Full Text] [Related]
9. The role and mechanism of AZD5363 anti-leukemia activity in T-cell acute lymphoblastic leukemia.
Luo D; Li S; Guo J; Yue H; Shi L; Liu R; Wang J; Shi X
Eur J Pharmacol; 2024 Jan; 963():176268. PubMed ID: 38096965
[TBL] [Abstract][Full Text] [Related]
10. Novel mechanism of napabucasin, a naturally derived furanonaphthoquinone: apoptosis and autophagy induction in lung cancer cells through direct targeting on Akt/mTOR proteins.
Petsri K; Thongsom S; Racha S; Chamni S; Jindapol S; Kaekratoke N; Zou H; Chanvorachote P
BMC Complement Med Ther; 2022 Sep; 22(1):250. PubMed ID: 36180880
[TBL] [Abstract][Full Text] [Related]
11. Anlotinib exerts potent antileukemic activities in Ph chromosome negative and positive B-cell acute lymphoblastic leukemia via perturbation of PI3K/AKT/mTOR pathway.
Chen Q; Lai Q; Jiang Y; Yao J; Chen Q; Zhang L; Wang C; Zhou Y; Deng M; Xu B
Transl Oncol; 2022 Nov; 25():101516. PubMed ID: 35985203
[TBL] [Abstract][Full Text] [Related]
12. Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts.
Fuka G; Kantner HP; Grausenburger R; Inthal A; Bauer E; Krapf G; Kaindl U; Kauer M; Dworzak MN; Stoiber D; Haas OA; Panzer-Grümayer R
Leukemia; 2012 May; 26(5):927-33. PubMed ID: 22094587
[TBL] [Abstract][Full Text] [Related]
13. Label-free-based quantitative proteomic analysis of the inhibition of cisplatin-resistant ovarian cancer cell proliferation by cucurbitacin B.
Yin S; Mai Z; Liu C; Xu L; Xia C
Phytomedicine; 2023 Mar; 111():154669. PubMed ID: 36681055
[TBL] [Abstract][Full Text] [Related]
14. Myricetin exhibit selective anti-lymphoma activity by targeting BTK and is effective via oral administration in vivo.
Song X; Rao H; Guo C; Yang B; Ren Y; Wang M; Li Y; Cao Z; Pei J
Phytomedicine; 2021 Dec; 93():153802. PubMed ID: 34710755
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
Sengupta TK; Leclerc GM; Hsieh-Kinser TT; Leclerc GJ; Singh I; Barredo JC
Mol Cancer; 2007 Jul; 6():46. PubMed ID: 17623090
[TBL] [Abstract][Full Text] [Related]
16. Investigation of the function of the PI3-Kinase / AKT signaling pathway for leukemogenesis and therapy of acute childhood lymphoblastic leukemia (ALL).
Ehm P; Grottke A; Bettin B; Jücker M
Cell Signal; 2022 May; 93():110301. PubMed ID: 35259456
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of FHL2 promotes tumorigenesis in cervical cancer and is correlated with poor prognosis.
Jin X; Jiao X; Jiao J; Zhang T; Cui B
Gene; 2018 Aug; 669():99-106. PubMed ID: 29800735
[TBL] [Abstract][Full Text] [Related]
18. Potential efficacy and prognosis of silencing the CRLF2‑mediated AKT/mTOR pathway in pediatric acute B‑cell lymphoblastic leukemia.
Jiang M; Zou X; Lu L
Oncol Rep; 2019 Feb; 41(2):885-894. PubMed ID: 30535452
[TBL] [Abstract][Full Text] [Related]
19. Fisetin inhibits laryngeal carcinoma through regulation of AKT/NF-κB/mTOR and ERK1/2 signaling pathways.
Zhang XJ; Jia SS
Biomed Pharmacother; 2016 Oct; 83():1164-1174. PubMed ID: 27551764
[TBL] [Abstract][Full Text] [Related]
20. VS-5584 as a PI3K/mTOR inhibitor enhances apoptotic effects of subtoxic dose arsenic trioxide via inhibition of NF-κB activity in B cell precursor-acute lymphoblastic leukemia.
Toosi B; Zaker F; Alikarami F; Kazemi A; Teremmahi Ardestanii M
Biomed Pharmacother; 2018 Jun; 102():428-437. PubMed ID: 29574283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
